BIOMAT Database Logo BIOMAT Database Logo

Antibody guided targeting of non-small cell lung cancer using 111In-labeled HMFG1 F(ab')2 fragments. 1988

H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.

Immunoscintigraphy using F(ab')2 fragments of tumor-associated monoclonal antibody HMFG1 was performed in 14 patients with primary and metastatic non-small cell carcinoma of lung cancer. The antibody was conjugated with diethylenetriamine pentaacetic acid and labeled with 111In. Quality control studies showed efficient incorporation of 111In onto antibody (5 mCi/mg), no significant loss of immunoreactivity, and in vitro and in vivo stability. The optimal time for imaging was between 48 and 72 h. Following i.v. administration, serum activity fell rapidly (t1/2a = 2.5 +/- 1.3 (SD) h; t1/2b = 42 +/- 4.5 h). The majority of the radioactivity was associated with the plasma and not with the blood cells. All patients had a significant concentration of 111In in the liver (approximately 20% of the injected dose, 48 h postadministration). No toxicity was encountered. No human antimurine-IgG antibody was detected in any of the patients within 4 months of follow-up, even in patients receiving two administrations of F(ab')2 fragments. Localization of all primary lesions and the majority (80%) of metastatic lesions was achieved. Seven of 14 patients were also studied using a 111In-labeled nonspecific antibody (Fab')2 fragment (4C4). In three patients the specificity index was higher than the other four (P less than 0.05). We conclude that although successful targeting of 111In-labeled (Fab')2 fragments of HMFG1 can be achieved in patients with non-small cell carcinoma of lung, observable tumor localization can also be achieved using a nonspecific antibody. Based on these findings, we recommend that in order to demonstrate specific radioimmunolocalization, patients with lung and possibly other tumor types should be studied using both specific and nonspecific antibodies.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D007205 Indium Radioisotopes Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes. Radioisotopes, Indium
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas

Related Publications

H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer.
January 2005, Anticancer research,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Immunoscintigraphy of lung cancer using 111In-labelled antiCEA F023C5-F(ab')2 fragments.
November 1991, Nuclear medicine communications,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Immunoscintigraphy using 111in-labelled F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of non-small cell lung carcinoma.
January 1994, European journal of cancer (Oxford, England : 1990),
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Targeting of non-small cell lung cancer using HMFG1-99mTc monoclonal antibodies.
January 1993, Medicinski pregled,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma.
January 1992, The Journal of clinical endocrinology and metabolism,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
August 2012, Molecular pharmaceutics,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
[Basic study for immunoscintigraphy of ovarian cancer using 99mTc labeled F(ab')2 fragments of monoclonal antibody].
April 1994, Kaku igaku. The Japanese journal of nuclear medicine,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Blocking activity of non-cytotoxic F (ab')2 tumor cell antibody fragments.
April 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
January 2015, Contrast media & molecular imaging,
H P Kalofonos, and G B Sivolapenko, and N S Courtenay-Luck, and D E Snook, and G R Hooker, and R Winter, and C G McKenzie, and J J Taylor-Papadimitriou, and P J Lavender, and A A Epenetos
Imaging lung cancer by scintigraphy with Indium 111-labeled F(ab')2 fragments of the anticarcinoembryonic antigen monoclonal antibody FO23C5.
August 1992, Cancer,
Copied contents to your clipboard!